| Gene symbol | ERBB2 | Synonyms | CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, p185(erbB2) | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | erb-b2 receptor tyrosine kinase 2 | ||||
| GTO ID | GTC2425 |
| Trial ID | NCT04511871 |
| Disease | Ovarian Cancer | Breast Cancer | Stomach Cancer | Sarcoma | Solid Tumor |
| Altered gene | HER2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CCT303-406 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors |
| Year | 2020 |
| Country | China |
| Company sponsor | Shanghai PerHum Therapeutics Co., Ltd. |
| Other ID(s) | CCT303-406-mST01 |
| Cohort 1 | |||||||||||||
|
|||||||||||||